The future of patient identification isn’t better analytics. It’s better clinical signal.
Life sciences organizations have invested heavily in larger datasets, more sophisticated analytics, and artificial intelligence (AI)-powered platforms to identify patients for clinical trials, real-world evidence, and commercial initiatives.
These technologies have created meaningful advances. Companies such as IQVIA, Komodo Health, TriNetX, Medidata, Deep6 AI, and Flatiron Health have built powerful platforms that aggregate and analyze healthcare data at an enormous scale.
But most share the same underlying assumption:
Clinical meaning can be reconstructed after the fact. That assumption is becoming the industry’s biggest limitation.
It also overlooks an important reality: clinically meaningful intent is often already present in structured EHR data. When that intent is captured in a computable and clinically grounded way, organizations can work from the original signal itself instead of trying to recreate meaning later.
The downstream problem
Most patient identification workflows begin after data has already been documented, coded, abstracted, and moved across multiple systems. At that point, organizations rely on claims data, retrospective EHR abstraction, broad code-based cohort definitions, and natural language processing (NLP) applied to existing notes.
These methods can generate valuable insights, but they are fundamentally trying to infer what the clinician originally meant.
Once clinical meaning is lost, it is difficult to recover with complete fidelity.
Industry and regulatory expectations are changing the standard
Recent academic research reinforces this challenge. In a 2026 npj Health Systems study, investigators introduced a computational framework for structuring and analyzing clinical trial eligibility criteria, highlighting how protocol requirements are frequently expressed in complex narrative language that must be translated into computable definitions before they can be applied to real-world data. This translation process is often manual, inconsistent, and difficult to reproduce.
For sponsors and CROs, the implication is significant. Precision patient identification depends not only on access to large volumes of data, but on a clinically grounded semantic layer capable of converting protocol intent into executable logic.
This need aligns with broader regulatory trends. As U.S. Food and Drug Administration has noted, advances in real-world data and analytics have increased the potential for real-world evidence to support regulatory decisions.
This shift is driving demand for:
- Prospective data capture
- Native traceability and lineage
- Standardized definitions
- Less downstream transformation
- Audit-ready evidence by design
In other words, regulatory-grade evidence begins when clinical information is first captured.
Take a reading break and schedule a demo to see our life sciences solutions in action.
Why AI alone is not enough
Artificial intelligence can accelerate screening and cohort construction, but AI is only as reliable as the data foundation beneath it.
As discussed in our blog about knowledge graphs, trustworthy AI depends on preserving clinical intent and grounding outputs in clinically meaningful relationships.
If documentation is inconsistent or coding misses nuance, downstream AI can only make educated guesses.
Structuring clinical data at the point of care
Most competitors focus on downstream analytics and orchestration. IMO Health starts earlier.
Embedded in every major EHR system and used by approximately 95% of U.S. providers, IMO Health captures and structures clinical intent at the point of care, before ambiguity propagates downstream.
This creates a stronger foundation for:
- Precision Patient Identification
- Protocol-aligned trial recruitment
- Regulatory-grade RWD and RWE
- Commercial point-of-care activation
- Real-time clinical activity signal
The next competitive advantage
As the industry moves toward computable protocols and audit-ready evidence, the strategic advantage will belong to organizations that can translate clinical intent into machine-executable logic without losing meaning.
Because the best cohort is not the one you clean fastest. It’s the one that was captured correctly from the beginning.
